JNJ-53718678 is a potent and orally available fusion inhibitor of the RSV virus, optimized from a prior oral inhibitor, BMS-433771. The prior inhibitor was challenged by moderate potency, suboptimal PK in preclinical species, limited lung distribution, and potential complications from CYP TDI due to an aminocyclopropyl moiety. The improved [...]
< 1 minute read
Sep. 18, 2021
JNJ-53718678: A Potent and Oral Fusion Inhibitor of RSV Virus
JNJ-53718678
potent, oral fusion inhibitor of RSV virus efficacious in Ph. 2a challenge study in HV from scaffold hop from known inhibitor J. Med. Chem., Jun. 15, 2020 Janssen Pharmaceutica NV, Beerse, BE
Loading...
